Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNAJC25-GNG10 readthrough protein is a chimeric protein product formed by co-transcription of the adjacent human DNAJC25 and GNG10 genes[1][3][10]. The resulting mRNA transcript incorporates the first exon of DNAJC25—encoding a member of the Hsp40 (DnaJ) co-chaperone family—and the last two exons of GNG10, which codes for the gamma subunit 10 of heterotrimeric G-proteins[1][3][10]. The resulting protein thus contains the N-terminus derived from DNAJC25 and the C-terminus from GNG10[3]. This readthrough event is relatively rare and its biological significance, distinct from the individual parent proteins, is unclear; no established function or disease association is annotated for the chimeric protein[3][10]. The parental protein, DNAJC25, is primarily involved in protein folding and cellular proteostasis as a co-chaperone to Hsp70, with notable downregulation observed in hepatocellular carcinoma and possible tumor suppressor functions[2][5]. GNG10 is part of the G protein family involved in signal transduction, but its physiological and disease roles remain incompletely detailed and are not specifically attributed to the readthrough product[3][5]. No drugs are known to specifically interact with the DNAJC25-GNG10 readthrough protein, nor are there mechanisms of action, biomarker roles, or safety concerns specific to this fusion product[3][10]. This readthrough locus and the resulting protein are documented in gene annotation resources, but current evidence suggests no independent therapeutic, diagnostic, or biomarker status.
None established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAJC25-GNG10 readthrough protein (DNAJC25-GNG10).